Justices Turn Away IP Cases Over MS Drug, Costly Prior Art
The U.S. Supreme Court started off its new term Monday by denying four cases looking at a patent covering a blockbuster multiple sclerosis treatment, when prior art is considered publicly accessible,...To view the full article, register now.
Already a subscriber? Click here to view full article